• Andringa, G., Lam, K.Y., Chegary, M., Wang, X., Chase, T.N., and Bennett, M.C. 2004. Tissue transglutaminase catalyzes the formation of α-synuclein crosslinks in Parkinson's disease. FASEB J. 18: 932934.
  • Bendit, E.G. and Ross, D. 1961. A technique for obtaining the ultraviolet absorption spectrum of solid keratin. Appl. Spectros. 15: 103105.
  • Bussell, R.Jr, Ramlall, T.F., and Eliezer, D. 2005. Helix periodicity, topology, and dynamics of membrane-associated α-synuclein. Protein Sci. 14: 862872.
  • Chen, P.S., Toribara, T.Y., and Warner, H. 1956. Microdetermination of phosphorus. Anal. Chem. 28: 17561758.
  • Eliezer, D., Kutluay, E., Bussell, R.Jr, and Browne, G. 2001. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 307: 10611073.
  • Jensen, P.H., Sørensen, E.S., Petersen, T.E., Gliemann, J., and Rasmussen, L.K. 1995. Residues in the synuclein consensus motif of the α-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid βA4 peptide. Biochem. J. 310: 9194.
  • Junn, E., Ronchetti, R.D., Quezado, M.M., Kim, S.Y., and Mouradian, M.M. 2003. Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. 100: 20472052.
  • Kim, S.-Y., Grant, P., Lee, J.H., Pant, H.C., and Steinert, P.M. 1999. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 274: 3071530721.
  • Konno, T., Morii, T., Hirata, A., Sato, S., Oiki, S., and Ikura, K. 2005a. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 44: 20722079.
  • Konno, T., Morii, T., Shimizu, H., Oiki, S., and Ikura, K. 2005b. Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J. Biol. Chem. 280: 1752017525.
  • Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T., and Lansbury, P.T.Jr 2002. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322: 10891102.
  • Lodish, H.F. 2000. Molecular cell biology, 4th ed. Freeman, New York.
  • Miller, M.L. and Johnson, G.V. 1995. Transglutaminase cross-linking of the τ protein. J. Neurochem. 65: 17601770.
  • Muma, N.A. 2007. Transglutaminase is linked to neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 66: 258263.
  • Murtaugh, M.P., Arend, W.P., and Davies, P.J. 1984. Induction of tissue transglutaminase in human peripheral blood monocytes. J. Exp. Med. 159: 114125.
  • Rockenstein, E., Hansen, L.A., Mallory, M., Trojanowski, J.Q., Galasko, D., and Masliah, E. 2001. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914: 4856.
  • Schults, C.W. 2006. Lewy bodies. Proc. Natl. Acad. Sci. 103: 16611668.
  • Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. 1997. α-Synuclein in Lewy bodies. Nature 388: 839840.
  • van der Werf, K.O., Putman, C.A.J., de Grooth, B.G., Segerink, F.B., Schipper, E.H., van Hulst, N.F., and Greve, J. 1993. Compact stand-alone atomic force microscope. Rev. Sci. Instrum. 64: 28922897.
  • van Raaij, M.E., Segers-Nolten, I.M., and Subramaniam, V. 2006. Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from α-synuclein mutants. Biophys. J. 91: L96L98. 10.1529/biophysj.106.090449.
  • Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., and Lansbury, P.T.Jr 2001. Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 78127819.
  • Wilhelmus, M.M., Boelens, W.C., Otte-Höller, I., Kamps, B., de Waal, R.M., and Verbeek, M.M. 2006. Small heat shock proteins inhibit amyloid-β protein aggregation and cerebrovascular amyloid-β protein toxicity. Brain Res. 1089: 6778.
  • Wilhelmus, M.M., van Dam, A.-M., and Drukarch, B. 2008. Tissue transglutaminase: A novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur. J. Pharmacol. 585: 464472.